Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T31391
(Former ID: TTDS00093)
|
|||||
Target Name |
Dipeptidyl peptidase 4 (DPP-4)
|
|||||
Synonyms |
Tcell activation antigen CD26; TP103; T-cell activation antigen CD26; Dipeptidyl peptidase IV; Dipeptidyl peptidase 4 soluble form; DPP-IV; DPP IV; DPP 4; CD26; Adenosine deaminase complexing protein-2; Adenosine deaminase complexing protein 2; ADCP2; ADCP-2; ADABP
Click to Show/Hide
|
|||||
Gene Name |
DPP4
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Acute diabete complication [ICD-11: 5A2Y] | |||||
2 | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
Function |
Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation. When overexpressed, enhanced cell proliferation, a process inhibited by GPC3. Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones. Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline. Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation.
Click to Show/Hide
|
|||||
BioChemical Class |
Peptidase
|
|||||
UniProt ID | ||||||
EC Number |
EC 3.4.14.5
|
|||||
Sequence |
MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLKNTYRLKLYSL
RWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNY VKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNL PSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSF YSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYL CDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPS EPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISN EYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLY TLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKY PLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGT FEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWE YYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQIS KALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
ADReCS ID | BADD_A00773 | |||||
HIT2.0 ID | T16UZ4 |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 6 Approved Drugs | + | ||||
1 | Alogliptin | Drug Info | Approved | Type-2 diabetes | [7], [8], [5] | |
2 | Anagliptin | Drug Info | Approved | Type-2 diabetes | [9], [10], [5] | |
3 | Kombiglyze XR/Komboglyze FDC | Drug Info | Approved | Diabetic complication | [11] | |
4 | Linagliptin | Drug Info | Approved | Type-2 diabetes | [12], [13] | |
5 | Saxagliptin | Drug Info | Approved | Type-2 diabetes | [14], [15], [5] | |
6 | Vildagliptin | Drug Info | Approved | Type-2 diabetes | [16], [17] | |
Clinical Trial Drug(s) | [+] 17 Clinical Trial Drugs | + | ||||
1 | Dutogliptin | Drug Info | Phase 3 | Type-2 diabetes | [20] | |
2 | LC-150444 | Drug Info | Phase 3 | Type-2 diabetes | [21] | |
3 | MK-3102 | Drug Info | Phase 3 | Type-2 diabetes | [22], [23] | |
4 | SAND-26 | Drug Info | Phase 3 | Autoimmune diabetes | [24], [25] | |
5 | SaxaDapa FDC | Drug Info | Phase 3 | Diabetic complication | [26], [27] | |
6 | SYR-472 | Drug Info | Phase 3 | Metabolic disorder | [28] | |
7 | Denagliptin | Drug Info | Phase 2/3 | Type-2 diabetes | [29] | |
8 | IP10 C8 | Drug Info | Phase 2 | Psoriasis vulgaris | [30] | |
9 | KRP-104 | Drug Info | Phase 2 | Type-2 diabetes | [31] | |
10 | Melogliptin | Drug Info | Phase 2 | Type-2 diabetes | [32] | |
11 | P32/98 | Drug Info | Phase 2 | Autism spectrum disorder | [33] | |
12 | PF-00734200 | Drug Info | Phase 2 | Type-2 diabetes | [34], [35] | |
13 | YSCMA | Drug Info | Phase 1/2 | Haematological malignancy | [36] | |
14 | DA-1229 | Drug Info | Phase 1 | Type-2 diabetes | [38] | |
15 | REC-01 | Drug Info | Phase 1 | Acute myocardial infarction | [39] | |
16 | Teneligliptin | Drug Info | Phase 1 | Type-2 diabetes | [40], [5] | |
17 | ZYDPLA 1 | Drug Info | Phase 1 | Type-2 diabetes | [5] | |
Discontinued Drug(s) | [+] 9 Discontinued Drugs | + | ||||
1 | ALS 2-0426 | Drug Info | Discontinued in Phase 2 | Type-2 diabetes | [41] | |
2 | NVP-DPP728 | Drug Info | Discontinued in Phase 2 | Type-2 diabetes | [42] | |
3 | PSN-9301 | Drug Info | Discontinued in Phase 2 | Diabetic complication | [43] | |
4 | R-1438 | Drug Info | Discontinued in Phase 2 | Type-2 diabetes | [44] | |
5 | TA-6666 | Drug Info | Discontinued in Phase 2 | Type-2 diabetes | [45] | |
6 | ABT-279 | Drug Info | Discontinued in Phase 1 | Type-2 diabetes | [47] | |
7 | TAK-100 | Drug Info | Discontinued in Phase 1 | Diabetic complication | [48] | |
8 | DSP-7238 | Drug Info | Terminated | Diabetic complication | [53] | |
9 | PT-630 | Drug Info | Terminated | Type-2 diabetes | [54] | |
Preclinical Drug(s) | [+] 2 Preclinical Drugs | + | ||||
1 | ASP8497 | Drug Info | Preclinical | Type-2 diabetes | [51] | |
2 | LY-2463665 | Drug Info | Preclinical | Type-2 diabetes | [52] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Inhibitor | [+] 116 Inhibitor drugs | + | ||||
1 | Alogliptin | Drug Info | [1], [17], [55] | |||
2 | Linagliptin | Drug Info | [58], [17] | |||
3 | Saxagliptin | Drug Info | [15], [17], [59] | |||
4 | Vildagliptin | Drug Info | [17] | |||
5 | Dutogliptin | Drug Info | [60] | |||
6 | LC-150444 | Drug Info | [61] | |||
7 | SYR-472 | Drug Info | [1], [57], [64] | |||
8 | Denagliptin | Drug Info | [17] | |||
9 | Melogliptin | Drug Info | [17] | |||
10 | P32/98 | Drug Info | [33] | |||
11 | DA-1229 | Drug Info | [68] | |||
12 | REC-01 | Drug Info | [39] | |||
13 | ZYDPLA 1 | Drug Info | [5] | |||
14 | Aminopiperidine derivative 1 | Drug Info | [69] | |||
15 | Aminopiperidine derivative 2 | Drug Info | [69] | |||
16 | Beta-phe compound 2 | Drug Info | [69] | |||
17 | Beta-phe compound 3 | Drug Info | [69] | |||
18 | Imidazo cyclohexylamine derivative 1 | Drug Info | [69] | |||
19 | Imidazo cyclohexylamine derivative 2 | Drug Info | [69] | |||
20 | Imidazo cyclohexylamine derivative 3 | Drug Info | [69] | |||
21 | Peptide analog 44 | Drug Info | [69] | |||
22 | Peptide analog 45 | Drug Info | [69] | |||
23 | Peptide analog 46 | Drug Info | [69] | |||
24 | Peptide analog 48 | Drug Info | [69] | |||
25 | Peptide analog 49 | Drug Info | [69] | |||
26 | Peptide analog 50 | Drug Info | [69] | |||
27 | Peptide analog 51 | Drug Info | [69] | |||
28 | PMID25482888-Compound-11 | Drug Info | [69] | |||
29 | PMID25482888-Compound-12 | Drug Info | [69] | |||
30 | PMID25482888-Compound-13 | Drug Info | [69] | |||
31 | PMID25482888-Compound-14 | Drug Info | [69] | |||
32 | PMID25482888-Compound-15 | Drug Info | [69] | |||
33 | PMID25482888-Compound-16 | Drug Info | [69] | |||
34 | PMID25482888-Compound-17 | Drug Info | [69] | |||
35 | PMID25482888-Compound-18 | Drug Info | [69] | |||
36 | PMID25482888-Compound-21 | Drug Info | [69] | |||
37 | PMID25482888-Compound-34 | Drug Info | [69] | |||
38 | PMID25482888-Compound-37 | Drug Info | [69] | |||
39 | PMID25482888-Compound-50 | Drug Info | [69] | |||
40 | PMID25482888-Compound-52 | Drug Info | [69] | |||
41 | PMID25482888-Compound-56 | Drug Info | [69] | |||
42 | PMID25482888-Compound-6 | Drug Info | [69] | |||
43 | PMID25482888-Compound-69 | Drug Info | [69] | |||
44 | PMID25482888-Compound-70 | Drug Info | [69] | |||
45 | PMID25482888-Compound-71 | Drug Info | [69] | |||
46 | PMID25482888-Compound-72 | Drug Info | [69] | |||
47 | Pyrimidine derivative 30 | Drug Info | [69] | |||
48 | Pyrimidine derivative 31 | Drug Info | [69] | |||
49 | Pyrimidine derivative 32 | Drug Info | [69] | |||
50 | Pyrimidine derivative 33 | Drug Info | [69] | |||
51 | Pyrimidinedione derivative 1 | Drug Info | [69] | |||
52 | Pyrrolo[1,2-f]triazine derivative 1 | Drug Info | [69] | |||
53 | Pyrrolo[1,2-f]triazine derivative 2 | Drug Info | [69] | |||
54 | Quinazoline derivative 1 | Drug Info | [69] | |||
55 | Thiomorpholine derivative 1 | Drug Info | [69] | |||
56 | Thiomorpholine derivative 2 | Drug Info | [69] | |||
57 | Triazole piperazine derivative 1 | Drug Info | [69] | |||
58 | Triazolo-pyrimidinedione derivative 1 | Drug Info | [69] | |||
59 | Triazolo-pyrimidinedione derivative 2 | Drug Info | [69] | |||
60 | Tricyclic heterocycle derivative 6 | Drug Info | [69] | |||
61 | Xanthine derivative 1 | Drug Info | [69] | |||
62 | Xanthine/amino piperidine compound 1 | Drug Info | [69] | |||
63 | ALS 2-0426 | Drug Info | [70] | |||
64 | NVP-DPP728 | Drug Info | [71] | |||
65 | PSN-9301 | Drug Info | [72] | |||
66 | R-1438 | Drug Info | [17] | |||
67 | TA-6666 | Drug Info | [73] | |||
68 | ABT-279 | Drug Info | [17] | |||
69 | TAK-100 | Drug Info | [1] | |||
70 | ASP8497 | Drug Info | [17] | |||
71 | LY-2463665 | Drug Info | [17] | |||
72 | DSP-7238 | Drug Info | [57] | |||
73 | (+/-)-6-(2-chlorophenyl)cyclohex-3-enamine | Drug Info | [75] | |||
74 | (1R,2R)-1,2-diphenylethane-1,2-diamine | Drug Info | [76] | |||
75 | (1R,2S)-1,2-diphenylethane-1,2-diamine | Drug Info | [76] | |||
76 | (2-(2-chlorophenyl)pyridin-3-yl)methanamine | Drug Info | [76] | |||
77 | (2s)-Pyrrolidin-2-Ylmethylamine | Drug Info | [77] | |||
78 | (3S,4R)-3-butyl-1-phenylpiperidin-4-amine | Drug Info | [78] | |||
79 | (5-phenyl-3H-benzo[d]imidazol-4-yl)methanamine | Drug Info | [79] | |||
80 | (R)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid | Drug Info | [80] | |||
81 | (S)-2-Amino-1-azetidin-1-yl-2-cyclohexyl-ethanone | Drug Info | [81] | |||
82 | (S)-2-Amino-1-thiazolidin-3-yl-propane-1-thione | Drug Info | [82] | |||
83 | (S)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone | Drug Info | [83] | |||
84 | (S)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone | Drug Info | [84] | |||
85 | 1-benzhydryl-3-butylpiperidin-4-amine | Drug Info | [78] | |||
86 | 1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine | Drug Info | [85] | |||
87 | 1-biphenyl-2-ylmethanamine | Drug Info | [86] | |||
88 | 2-(2-chlorophenyl)-2-morpholinoethanamine | Drug Info | [76] | |||
89 | 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One | Drug Info | [87] | |||
90 | 3-butyl-1-(naphthalen-1-yl)piperidin-4-amine | Drug Info | [78] | |||
91 | 4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine | Drug Info | [85] | |||
92 | 4-(2,4-dichlorophenyl)-1-tosylpyrrolidin-3-amine | Drug Info | [85] | |||
93 | 4-iodophenyl-alaninyl-(S)-2-cyano-pyrrolidine | Drug Info | [88] | |||
94 | ABT-341 | Drug Info | [75] | |||
95 | Alpha-D-Mannose | Drug Info | [87] | |||
96 | ASC-201 | Drug Info | [57] | |||
97 | BPI-711001 | Drug Info | [57] | |||
98 | C-(2'-Chloro-biphenyl-2-yl)-methylamine | Drug Info | [76] | |||
99 | Cyclohexylglycine-(2S)-cyanopyrrolidine | Drug Info | [89] | |||
100 | D-420720 | Drug Info | [57] | |||
101 | D-Val-L-boroPro | Drug Info | [90] | |||
102 | DB-160 | Drug Info | [57] | |||
103 | Diisopropylphosphono Group | Drug Info | [87] | |||
104 | DIPROTIN A | Drug Info | [91] | |||
105 | EMC-0901 | Drug Info | [57] | |||
106 | FE 999011 | Drug Info | [93] | |||
107 | Fucose | Drug Info | [87] | |||
108 | Iodo-Phenylalanine | Drug Info | [87] | |||
109 | KR-62436 | Drug Info | [94] | |||
110 | L-Ala-L-boroPro | Drug Info | [90] | |||
111 | L-Val-L-boroPro | Drug Info | [90] | |||
112 | N-isoleucylthiazolidine | Drug Info | [89] | |||
113 | N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine | Drug Info | [95] | |||
114 | PK-44 | Drug Info | [57] | |||
115 | PMID20684603C24dd | Drug Info | [96] | |||
116 | Retagliptin | Drug Info | [57] | |||
Modulator | [+] 10 Modulator drugs | + | ||||
1 | Anagliptin | Drug Info | [56] | |||
2 | Kombiglyze XR/Komboglyze FDC | Drug Info | [57] | |||
3 | MK-3102 | Drug Info | [62] | |||
4 | SaxaDapa FDC | Drug Info | [26], [27] | |||
5 | IP10 C8 | Drug Info | [30] | |||
6 | KRP-104 | Drug Info | [65] | |||
7 | PF-00734200 | Drug Info | [66] | |||
8 | Teneligliptin | Drug Info | [57] | |||
9 | PT-630 | Drug Info | [74] | |||
10 | E-3024 | Drug Info | [92] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Alogliptin | Ligand Info | |||||
Structure Description | Crystal structure of dipeptidyl peptidase IV in complex with TAK-322 | PDB:3G0B | ||||
Method | X-ray diffraction | Resolution | 2.25 Å | Mutation | No | [97] |
PDB Sequence |
RKTYTLTDYL
49 KNTYRLKLYS59 LRWISDHEYL69 YKQENNILVF79 NAEYGNSSVF89 LENSTFDEFG 99 HSINDYSISP109 DGQFILLEYN119 YVKQWRHSYT129 ASYDIYDLNK139 RQLITEERIP 149 NNTQWVTWSP159 VGHKLAYVWN169 NDIYVKIEPN179 LPSYRITWTG189 KEDIIYNGIT 199 DWVYEEEVFS209 AYSALWWSPN219 GTFLAYAQFN229 DTEVPLIEYS239 FYSDESLQYP 249 KTVRVPYPKA259 GAVNPTVKFF269 VVNTDSLSSV279 TNATSIQITA289 PASMLIGDHY 299 LCDVTWATQE309 RISLQWLRRI319 QNYSVMDICD329 YDESSGRWNC339 LVARQHIEMS 349 TTGWVGRFRP359 SEPHFTLDGN369 SFYKIISNEE379 GYRHICYFQI389 DKKDCTFITK 399 GTWEVIGIEA409 LTSDYLYYIS419 NEYKGMPGGR429 NLYKIQLSDY439 TKVTCLSCEL 449 NPERCQYYSV459 SFSKEAKYYQ469 LRCSGPGLPL479 YTLHSSVNDK489 GLRVLEDNSA 499 LDKMLQNVQM509 PSKKLDFIIL519 NETKFWYQMI529 LPPHFDKSKK539 YPLLLDVYAG 549 PCSQKADTVF559 RLNWATYLAS569 TENIIVASFD579 GRGSGYQGDK589 IMHAINRRLG 599 TFEVEDQIEA609 ARQFSKMGFV619 DNKRIAIWGW629 SYGGYVTSMV639 LGSGSGVFKC 649 GIAVAPVSRW659 EYYDSVYTER669 YMGLPTPEDN679 LDHYRNSTVM689 SRAENFKQVE 699 YLLIHGTADD709 NVHFQQSAQI719 SKALVDVGVD729 FQAMWYTDED739 HGIASSTAHQ 749 HIYTHMSHFI759 KQCFSLP
|
|||||
|
||||||
Ligand Name: Linagliptin | Ligand Info | |||||
Structure Description | Crystal structure of complex of human DPP4 and inhibitor | PDB:2RGU | ||||
Method | X-ray diffraction | Resolution | 2.60 Å | Mutation | No | [98] |
PDB Sequence |
SRKTYTLTDY
48 LKNTYRLKLY58 SLRWISDHEY68 LYKQENNILV78 FNAEYGNSSV88 FLENSTFDEF 98 GHSINDYSIS108 PDGQFILLEY118 NYVKQWRHSY128 TASYDIYDLN138 KRQLITEERI 148 PNNTQWVTWS158 PVGHKLAYVW168 NNDIYVKIEP178 NLPSYRITWT188 GKEDIIYNGI 198 TDWVYEEEVF208 SAYSALWWSP218 NGTFLAYAQF228 NDTEVPLIEY238 SFYSDESLQY 248 PKTVRVPYPK258 AGAVNPTVKF268 FVVNTDSLSS278 VTNATSIQIT288 APASMLIGDH 298 YLCDVTWATQ308 ERISLQWLRR318 IQNYSVMDIC328 DYDESSGRWN338 CLVARQHIEM 348 STTGWVGRFR358 PSEPHFTLDG368 NSFYKIISNE378 EGYRHICYFQ388 IDKKDCTFIT 398 KGTWEVIGIE408 ALTSDYLYYI418 SNEYKGMPGG428 RNLYKIQLSD438 YTKVTCLSCE 448 LNPERCQYYS458 VSFSKEAKYY468 QLRCSGPGLP478 LYTLHSSVND488 KGLRVLEDNS 498 ALDKMLQNVQ508 MPSKKLDFII518 LNETKFWYQM528 ILPPHFDKSK538 KYPLLLDVYA 548 GPCSQKADTV558 FRLNWATYLA568 STENIIVASF578 DGRGSGYQGD588 KIMHAINRRL 598 GTFEVEDQIE608 AARQFSKMGF618 VDNKRIAIWG628 WSYGGYVTSM638 VLGSGSGVFK 648 CGIAVAPVSR658 WEYYDSVYTE668 RYMGLPTPED678 NLDHYRNSTV688 MSRAENFKQV 698 EYLLIHGTAD708 DNVHFQQSAQ718 ISKALVDVGV728 DFQAMWYTDE738 DHGIASSTAH 748 QHIYTHMSHF758 IKQCFSLP
|
|||||
|
||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Protein digestion and absorption | hsa04974 | Affiliated Target |
|
Class: Organismal Systems => Digestive system | Pathway Hierarchy |
Degree | 14 | Degree centrality | 1.50E-03 | Betweenness centrality | 2.15E-03 |
---|---|---|---|---|---|
Closeness centrality | 2.25E-01 | Radiality | 1.40E+01 | Clustering coefficient | 7.69E-02 |
Neighborhood connectivity | 2.59E+01 | Topological coefficient | 9.21E-02 | Eccentricity | 12 |
Download | Click to Download the Full PPI Network of This Target | ||||
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 1 KEGG Pathways | + | ||||
1 | Protein digestion and absorption | |||||
NetPath Pathway | [+] 2 NetPath Pathways | + | ||||
1 | IL2 Signaling Pathway | |||||
2 | TGF_beta_Receptor Signaling Pathway |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of Takeda (2009). | |||||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6286). | |||||
REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022044. | |||||
REF 4 | 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. | |||||
REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018 | |||||
REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6319). | |||||
REF 8 | Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. | |||||
REF 9 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 10 | ClinicalTrials.gov (NCT02330406) Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial. U.S. National Institutes of Health. | |||||
REF 11 | KOMBIGLYZE XR tablets approved in the US for the treatment of type 2 diabetes mellitus in adults | |||||
REF 12 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6318). | |||||
REF 13 | Clinical pipeline report, company report or official report of Boehringer Ingelheim. | |||||
REF 14 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6316). | |||||
REF 15 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. | |||||
REF 16 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6310). | |||||
REF 17 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | |||||
REF 18 | ClinicalTrials.gov (NCT01798238) Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||||
REF 19 | ClinicalTrials.gov (NCT01990469) Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin. U.S. National Institutes of Health. | |||||
REF 20 | ClinicalTrials.gov (NCT00690638) Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||||
REF 21 | ClinicalTrials.gov (NCT02089126) Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes. U.S.National Institutes of Health. | |||||
REF 22 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8402). | |||||
REF 23 | ClinicalTrials.gov (NCT01703208) A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018). U.S. National Institutes of Health. | |||||
REF 24 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8691). | |||||
REF 25 | ClinicalTrials.gov (NCT02411084) Study of BEGEDINA vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD. U.S. National Institutes of Health. | |||||
REF 26 | Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7. | |||||
REF 27 | The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12. | |||||
REF 28 | Clinical pipeline report, company report or official report of Takeda. | |||||
REF 29 | ClinicalTrials.gov (NCT00387972) Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM). U.S. National Institutes of Health. | |||||
REF 30 | Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61. | |||||
REF 31 | ClinicalTrials.gov (NCT00525330) A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone. U.S. National Institutes of Health. | |||||
REF 32 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021640) | |||||
REF 33 | Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 2002 Apr;51(4):943-50. | |||||
REF 34 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7413). | |||||
REF 35 | ClinicalTrials.gov (NCT00473525) 12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin. U.S. National Institutes of Health. | |||||
REF 36 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031210) | |||||
REF 37 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028500) | |||||
REF 38 | ClinicalTrials.gov (NCT00961025) A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects. U.S. National Institutes of Health. | |||||
REF 39 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 40 | ClinicalTrials.gov (NCT02449330) Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study. | |||||
REF 41 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022304) | |||||
REF 42 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012640) | |||||
REF 43 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019065) | |||||
REF 44 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018193) | |||||
REF 45 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020875) | |||||
REF 46 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022199) | |||||
REF 47 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025075) | |||||
REF 48 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028364) | |||||
REF 49 | 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl pepti... J Pharmacol Exp Ther. 2006 Dec;319(3):1253-7. | |||||
REF 50 | Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009 Dec;119(12):3613-25. | |||||
REF 51 | ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem Pharmacol. 2008 Jul 1;76(1):98-107. | |||||
REF 52 | Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem. 2012 Oct 1;20(19):5705-19. | |||||
REF 53 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028616) | |||||
REF 54 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022168) | |||||
REF 55 | Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db... Br J Pharmacol. 2009 Jun;157(3):415-26. | |||||
REF 56 | Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30. | |||||
REF 57 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). | |||||
REF 58 | Boehringer Ingelheim. Product Development Pipeline. June 2 2009. | |||||
REF 59 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||||
REF 60 | Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55. | |||||
REF 61 | Clinical pipeline report, company report or official report of ShangHai APIs Chemical. | |||||
REF 62 | Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12. | |||||
REF 63 | Clinical pipeline report, company report or official report of Siesonline. | |||||
REF 64 | SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32. | |||||
REF 65 | Clinical pipeline report, company report or official report of Activx. | |||||
REF 66 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.Diabet Med.2011 Apr;28(4):464-9. | |||||
REF 67 | Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue. Diagn Pathol. 2014 Feb 6;9:30. | |||||
REF 68 | DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012 Jan 2;90(1-2):21-9. | |||||
REF 69 | DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. | |||||
REF 70 | Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews April 2012 vol. 64 no. 2 188-237. | |||||
REF 71 | A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Eur J Med Chem. 2008 Aug;43(8):1603-11. | |||||
REF 72 | Navigating the chemical space of dipeptidyl peptidase-4 inhibitors. Drug Des Devel Ther. 2015; 9: 4515-4549. | |||||
REF 73 | Dipeptidyl Peptidase-4 Inhibitors Clinical data and clinical implications. before print March 2, 2007. | |||||
REF 74 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
REF 75 | Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)... J Med Chem. 2006 Nov 2;49(22):6439-42. | |||||
REF 76 | In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9. | |||||
REF 77 | DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. | |||||
REF 78 | 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2966-70. | |||||
REF 79 | Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2362-7. | |||||
REF 80 | Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem. 2008 Oct 9;51(19):6005-13. | |||||
REF 81 | New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4770-3. | |||||
REF 82 | Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg Med Chem Lett. 2002 Oct 21;12(20):2825-8. | |||||
REF 83 | Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. Bioorg Med Chem. 2008 Feb 15;16(4):1613-31. | |||||
REF 84 | [(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2618-21. | |||||
REF 85 | Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibito... Bioorg Med Chem Lett. 2007 Apr 1;17(7):2005-12. | |||||
REF 86 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||||
REF 87 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 88 | Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2006 Jan 1;16(1):123-8. | |||||
REF 89 | 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioava... J Med Chem. 2006 Jan 12;49(1):373-80. | |||||
REF 90 | Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines. J Med Chem. 2007 May 17;50(10):2391-8. | |||||
REF 91 | Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg Med Chem Lett. 2008 Jan 15;18(2):479-84. | |||||
REF 92 | E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-o ne tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.Eur J Pharmacol.2006 Oct 24;548(1-3):181-7. | |||||
REF 93 | Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes. 2002 May;51(5):1461-9. | |||||
REF 94 | Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem. 2009 Mar 1;17(5):1783-802. | |||||
REF 95 | Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4777-9. | |||||
REF 96 | Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8. | |||||
REF 97 | Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J Med Chem. 2011 Jan 27;54(2):510-24. | |||||
REF 98 | 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, sele... J Med Chem. 2007 Dec 27;50(26):6450-3. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.